Karyopharm Therapeutics Inc.

Thank you. . . . . . . Thank you. Thank you.

good morning everybody my name is kelsey and i will be your conference operator for today at this time i would like to welcome everyone to the karyo farm therapeutics first quarter 2026 financial results conference call There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Mr. Brennan Strong, Senior Vice President, Investor Relations. Please go ahead.

Good morning, and thank you all for joining us on today's conference call to discuss CarioFarm's first quarter 2026 financial results and recent company progress. We issued a press release this morning detailing our financial results for the first quarter of 2026. This release, along with a slide presentation that we will reference during our call today, are available on our website. For today's call, as seen on slide two, I'm joined by Richard, Rajma, Sohania, and Lori, who will provide an update on the results for the first quarter, highlight the importance of the results from our Phase III Sentry Trial in Myelofibrosis, and provide an update on our Endometrial Cancer Program and related commercial opportunity. Before we begin our formal comments, I'll remind you that various remarks we will make today constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 as outlined on slide three. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the risk factor section of our most recent form 10Q or 10K on file with the SEC and in other filings we may make in the future with the SEC. Any forward-looking statements represent our views as of today only. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change. Therefore, you should not rely on these forward-looking statements as representing our views as of any later date. I'll now turn the call over to Richard. Please turn to slide five.